Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

Cancer Cell

Volumn 28, Issue 6, 2015, Pages 773-784

  Tateishi, Kensuke ^a   Wakimoto, Hiroaki ^a   Iafrate, A John ^a   Tanaka, Shota ^a   Loebel, Franziska ^a   Lelic, Nina ^a   Wiederschain, Dmitri ^b   Bedel, Olivier ^b   Deng, Gejing ^b   Zhang, Bailin ^b   He, Timothy ^b   Shi, Xu ^a   Gerszten, Robert E ^a   Zhang, Yiyun ^a   Yeh, Jing Ruey J ^a   Curry, William T ^a   Zhao, Dan ^a   Sundaram, Sudhandra ^a   Nigim, Fares ^a   Koerner, Mara V A ^a   Ho, Quan ^a   Fisher, David E ^a   Roider, Elisabeth M ^a   Kemeny, Lajos V ^a   Samuels, Yardena ^c   Flaherty, Keith T ^a   Batchelor, Tracy T ^a   Chi, Andrew S ^a,d   Cahill, Daniel P ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b Sanofi Oncology   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ADENYLATE KINASE; ISOCITRATE DEHYDROGENASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE 1; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; ANTINEOPLASTIC AGENT; CYTOKINE; ENZYME INHIBITOR; GLUTARIC ACID DERIVATIVE; GLYCOSYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL ENERGY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL PROLIFERATION; COMPARATIVE STUDY; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; HEK293 CELL LINE; METABOLISM; METABOLOMICS; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; MUTATION; PATHOLOGY; PROCEDURES; SCID MOUSE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL CULTURE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BRAIN NEOPLASMS; CELL PROLIFERATION; CYTOKINES; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; GLUTARATES; HEK293 CELLS; HUMANS; ISOCITRATE DEHYDROGENASE; METABOLOMICS; MICE, SCID; MOLECULAR TARGETED THERAPY; MUTATION; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTOSYLTRANSFERASES; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956792514     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.11.006     Document Type: Article

References (62)

1. Amary M.F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., Pollock R., O'Donnell P., Grigoriadis A., Diss T., et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 2011, 224:334-343.
2. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
3. Borodovsky A., Salmasi V., Turcan S., Fabius A.W., Baia G.S., Eberhart C.G., Weingart J.D., Gallia G.L., Baylin S.B., Chan T.A., Riggins G.J. 5-azacitidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013, 4:1737-1747.
4. Cairncross J.G., Wang M., Jenkins R.B., Shaw E.G., Giannini C., Brachman D.G., Buckner J.C., Fink K.L., Souhami L., Laperriere N.J., et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J. Clin. Oncol. 2014, 32:783-790.
5. Cairns R.A., Iqbal J., Lemonnier F., Kucuk C., de Leval L., Jais J.P., Parrens M., Martin A., Xerri L., Brousset P., et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119:1901-1903.
6. IDH1 inhibitor shows promising early results. Cancer Discov. 2015, 5:4. Cancer Discovery.
7. Cerna D., Li H., Flaherty S., Takebe N., Coleman C.N., Yoo S.S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J. Biol. Chem. 2012, 287:22408-22417.
8. Chen C., Liu Y., Lu C., Cross J.R., Morris J.P., Shroff A.S., Ward P.S., Bradner J.E., Thompson C., Lowe S.W. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013, 27:1974-1985.
9. Chiarugi A., Dölle C., Felici R., Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat. Rev. Cancer 2012, 12:741-752.
10. Chowdhury R., Yeoh K.K., Tian Y.M., Hillringhaus L., Bagg E.A., Rose N.R., Leung I.K., Li X.S., Woon E.C., Yang M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011, 12:463-469.
11. Cuyàs E., Fernández-Arroyo S., Corominas-Faja B., Rodríguez-Gallego E., Bosch-Barrera J., Martin-Castillo B., De Llorens R., Joven J., Menendez J.A. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 2015, 6:12279-12296.
12. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
13. Deng G., Shen J., Yin M., McManus J., Mathieu M., Gee P., He T., Shi C., Bedel O., McLean L.R., et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J. Biol. Chem. 2015, 290:762-774.
14. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
15. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
16. Galli U., Travelli C., Massarotti A., Fakhfouri G., Rahimian R., Tron G.C., Genazzani A.A. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J. Med. Chem. 2013, 56:6279-6296.
17. Grassian A.R., Parker S.J., Davidson S.M., Divakaruni A.S., Green C.R., Zhang X., Slocum K.L., Pu M., Lin F., Vickers C., et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014, 74:3317-3331.
18. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8:774-785.
19. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009, 118:469-474.
20. Hasmann M., Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63:7436-7442.
21. Hjarnaa P.J., Jonsson E., Latini S., Dhar S., Larsson R., Bramm E., Skov T., Binderup L. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 1999, 59:5751-5757.
22. Izquierdo-Garcia J.L., Cai L.M., Chaumeil M.M., Eriksson P., Robinson A.E., Pieper R.O., Phillips J.J., Ronen S.M. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase. PLoS ONE 2014, 9:e108289.
23. Johnson B.E., Mazor T., Hong C., Barnes M., Aihara K., McLean C.Y., Fouse S.D., Yamamoto S., Ueda H., Tatsuno K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193.
24. Kaelin W.G. SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Cancer Cell 2009, 16:180-182.
25. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
26. Kipp B.R., Voss J.S., Kerr S.E., Barr Fritcher E.G., Graham R.P., Zhang L., Highsmith W.E., Zhang J., Roberts L.R., Gores G.J., Halling K.C. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum. Pathol. 2012, 43:1552-1558.
27. Koivunen P., Lee S., Duncan C.G., Lopez G., Lu G., Ramkissoon S., Losman J.A., Joensuu P., Bergmann U., Gross S., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
28. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15:110-121.
29. Leonardi R., Subramanian C., Jackowski S., Rock C.O. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J. Biol. Chem. 2012, 287:14615-14620.
30. Losman J.A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
31. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
32. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrózek K., Margeson D., Holland K.B., Whitman S.P., Becker H., Schwind S., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2010, 28:2348-2355.
33. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361:1058-1066.
34. Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., Jewell C.M., Johnson Z.R., Irvine D.J., Guarente L., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-384.
35. Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., DeBerardinis R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012, 481:385-388.
36. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. Cancer Genome Atlas Research Network.
37. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
38. Popovici-Muller J., Saunders J.O., Salituro F.G., Travins J.M., Yan S., Zhao F., Gross S., Dang L., Yen K.E., Yang H., et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med. Chem. Lett. 2012, 3:850-855.
39. Reitman Z.J., Jin G., Karoly E.D., Spasojevic I., Yang J., Kinzler K.W., He Y., Bigner D.D., Vogelstein B., Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 2011, 108:3270-3275.
40. Reitman Z.J., Duncan C.G., Poteet E., Winters A., Yan L.J., Gooden D.M., Spasojevic I., Boros L.G., Yang S.H., Yan H. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J. Biol. Chem. 2014, 289:23318-23328.
41. Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., Tsoi J., Clark O., Oldrini B., Komisopoulou E., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
42. Saha S.K., Parachoniak C.A., Ghanta K.S., Fitamant J., Ross K.N., Najem M.S., Gurumurthy S., Akbay E.A., Sia D., Cornella H., et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2014, 513:110-114.
43. Sasaki M., Knobbe C.B., Munger J.C., Lind E.F., Brenner D., Brüstle A., Harris I.S., Holmes R., Wakeham A., Haight J., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488:656-659.
44. Seltzer M.J., Bennett B.D., Joshi A.D., Gao P., Thomas A.G., Ferraris D.V., Tsukamoto T., Rojas C.J., Slusher B.S., Rabinowitz J.D., et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70:8981-8987.
45. Shames D.S., Elkins K., Walter K., Holcomb T., Du P., Mohl D., Xiao Y., Pham T., Haverty P.M., Liederer B., et al. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin. Cancer Res. 2013, 19:6912-6923.
46. Suijker J., Oosting J., Koornneef A., Struys E.A., Salomons G.S., Schaap F.G., Waaijer C.J., Wijers-Koster P.M., Briaire-de Bruijn I.H., Haazen L., et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget 2015, 6:12505-12519.
47. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
48. Turcan S., Fabius A.W., Borodovsky A., Pedraza A., Brennan C., Huse J., Viale A., Riggins G.J., Chan T.A. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget 2013, 4:1729-1736.
49. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
50. Wakimoto H., Kesari S., Farrell C.J., Curry W.T., Zaupa C., Aghi M., Kuroda T., Stemmer-Rachamimov A., Shah K., Liu T.C., et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009, 69:3472-3481.
51. Wakimoto H., Tanaka S., Curry W.T., Loebel F., Zhao D., Tateishi K., Chen J., Klofas L.K., Lelic N., Kim J.C., et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin. Cancer Res. 2014, 20:2898-2909.
52. Wang P., Dong Q., Zhang C., Kuan P.F., Liu Y., Jeck W.R., Andersen J.B., Jiang W., Savich G.L., Tan T.X., et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013, 32:3091-3100.
53. Wang F., Travins J., DeLaBarre B., Penard-Lacronique V., Schalm S., Hansen E., Straley K., Kernytsky A., Liu W., Gliser C., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013, 340:622-626.
54. Ward P.S., Cross J.R., Lu C., Weigert O., Abel-Wahab O., Levine R.L., Weinstock D.M., Sharp K.A., Thompson C.B. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 2012, 31:2491-2498.
55. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009, 174:1149-1153.
56. Watson M., Roulston A., Bélec L., Billot X., Marcellus R., Bédard D., Bernier C., Branchaud S., Chan H., Dairi K., et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 2009, 29:5872-5888.
57. Wise D.R., Ward P.S., Shay J.E., Cross J.R., Gruber J.J., Sachdeva U.M., Platt J.M., DeMatteo R.G., Simon M.C., Thompson C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 2011, 108:19611-19616.
58. Wosikowski K., Mattern K., Schemainda I., Hasmann M., Rattel B., Löser R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res. 2002, 62:1057-1062.
59. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
60. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
61. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J.K., Markowitz S., Zhou S., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
62. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.